Since dnCRTC acts as a pan-CRTC inhibitor, it has the potential to serve as an invaluable research tool for dissecting the role of deregulated CRTC activation in various disease settings, such as cancers with aberrant CRTC activation (e.g. LKB1 deficiency, the CRTC1-MAML2 fusion), diabetes with CRTC activation that contributes to high blood glucose levels as well as neurological conditions such as depression and memory. The gene discussed is CRTC1; the disease is cancer.